AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 188 filers reported holding AKERO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,875,086 | +28.8% | 76,613 | +18.9% | 0.00% | 0.0% |
| Q2 2023 | $3,008,237 | +36.4% | 64,430 | +11.7% | 0.00% | +100.0% |
| Q1 2023 | $2,205,995 | -26.2% | 57,658 | +4.4% | 0.00% | -50.0% |
| Q4 2022 | $2,987,594 | +292.4% | 55,243 | +131.9% | 0.00% | +100.0% |
| Q3 2022 | $761,440 | +545.4% | 23,826 | +90.9% | 0.00% | – |
| Q2 2022 | $117,974 | -28.5% | 12,484 | +7.4% | 0.00% | – |
| Q1 2022 | $164,902 | -45.4% | 11,621 | -18.0% | 0.00% | – |
| Q4 2021 | $302,000 | -5.9% | 14,169 | -1.5% | 0.00% | – |
| Q3 2021 | $321,000 | -15.3% | 14,382 | -5.8% | 0.00% | – |
| Q2 2021 | $379,000 | +53.4% | 15,260 | +78.9% | 0.00% | – |
| Q1 2021 | $247,000 | +8.3% | 8,529 | -3.3% | 0.00% | – |
| Q4 2020 | $228,000 | -6.6% | 8,824 | +11.5% | 0.00% | – |
| Q3 2020 | $244,000 | – | 7,917 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $125,180,178 | 50.58% |
| COMMODORE CAPITAL LP | 790,000 | $30,225,400 | 4.60% |
| Redmile Group, LLC | 2,044,389 | $78,218,323 | 3.39% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 202,561 | $7,749,984 | 3.20% |
| Ghost Tree Capital, LLC | 275,000 | $10,522,000 | 3.11% |
| Avidity Partners Management LP | 2,447,000 | $93,622,220 | 3.11% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $22,736,043 | 3.08% |
| Logos Global Management LP | 400,000 | $15,304,000 | 2.19% |
| Yiheng Capital Management, L.P. | 1,125,791 | $43,072,764 | 1.70% |
| Boxer Capital, LLC | 831,495 | $31,813 | 1.56% |